There are concerns about altered vascular functions that could play an important role in the pathogenesis and influence the severity of chronic disease, however, increased cardiovascular risk in paediatric cystic fibrosis (CF) has not been yet fully understood. Aim was to analyse vascular disease risk and investigate changes over times in CF and controls. We prospectively enrolled 22 CF subjects (a median age of 16.07 years), and 22 healthy demographically matched controls (a median age of 17.28 years) and determined endothelial function. We utilised a combined diagnostic approach by measuring the plethysmographic Reactive Hyperemia Index (RHI) as the post-to preocclusive endothelium-dependent changes of vascular tone, and biomarkers that are known to be related to endothelial dysfunction (ED): asymmetric dimethyl arginine (ADMA), high-sensitive CRP (hsCRP), VCAM-1 and E-selectin. RHI values were significantly lower in CF young adults (p<0.005). HsCRP (p<0.005), E-selectin (p<0.001) and VCAM-1 (p<0.001) were significantly increased in CF patients since childhood. The findings have provided a detailed account of the ongoing process of microvascular dysfunction with gradual progression with the age of CF patients, making them further at risk of advanced vascular disease. Elevations of biomarkers in CF children with not yet demonstrated RHI changes but with significantly reduced RHI in adulthood and lipid profile changes indicate the possible occurrence of ED with CF-related specific risk factors over time and will enable us to provide the best possible support.

Department of Pediatrics Charles University Prague Faculty of Medicine in Pilsen Faculty Hospital Pilsen Czech Republic

Zobrazit více v PubMed

ALLAN RB, DELANEY CL, MILLER MD, SPARK JI. A comparison of flow-mediated dilatation and peripheral artery tonometry for measurment of endothelial function in healthy individuals and patients with peripheral artrial disease. Eur J Vasc Endovasc Surg. 2013;45:263–269. doi: 10.1016/j.ejvs.2012.12.002. PubMed DOI

AIRLEY RE, MONAGHAN JE, STRATFORD IJ. Hypoxia and disease: opportunities for novel diagnostic and therapeutic prodrug strategies. Pharm J. 2000;264:666–673.

BECKER BF, JACOB M, LEIPERT S, SALMON AH, CHAPPELL D. Degradation of the endothelial glycocalyx in clinical settings: searching for the sheddases. Br J Clin Pharmacol. 2015;80:389–402. doi: 10.1111/bcp.12629. PubMed DOI PMC

BONNETI PO, LERMAN LO, LERMAN A. Endothelial dysfunction - A marker of Atherosclerotic Risk. Arterioscler Thromb Vasc Bio. 2003;23:168–175. doi: 10.1161/01.ATV.0000051384.43104.FC. PubMed DOI

BUEHLER T, STEINMANN M, SINGER F, REGAMEY N, CASAULTA C, SCHOENI MH, SIMONETTI GD. Increased arterial stiffness in children with cystic fibrosis. Eur Respir J. 2012;39:1536–1537. doi: 10.1183/09031936.00212511. PubMed DOI

CASTELLANI C, DUFF AJA, BELL SC, HEIJERMAN HGM, MUNCK A, RATJEN F, SERMET-GAUDELUS I, SOUTHERN KW, BARBEN J, FLUME PA, HODKOVÁ P, KASHIRSKAYA N, KIRSZENBAUM MN, MADGE S, OXLEY H, PLANT B, SCHWARZENBERG SJ, SMYTH AR, TACCETTI G, WAGNER TOF, WOLFE SP, DREVINEK P. ECFS best practice guidelines: the 2018 revision. J Cyst Fibros. 2018;17:153–178. doi: 10.1016/j.jcf.2018.02.006. PubMed DOI

CROSS CE, REVERRI EJ, MORRISSEY BM. Joining the crowd: cystic fibrosis and cardiovascular disease risk factors. Chest. 2013;143:882–884. doi: 10.1378/chest.12-2444. PubMed DOI

ČEJKOVÁ S, KRÁLOVÁ LESNÁ I, FRONĚK J, JANOUŠK L, KRÁLOVÁ A, ŽDYCHOVÁ J, POLEDNE R. Pro-inflammatory gene expression in adipose tissue of patients with atherosclerosis. Physiol Res. 2017;66:633–640. doi: 10.33549/physiolres.933352. PubMed DOI

De ROSE V, OLIVA A, MESSORE B, GROSSO B, MOLLAR C, POZZI E. Circulating adhesion molecules in cystic fibrosis. Am J Respir Crit Care Med. 1998;157:1234–1239. doi: 10.1164/ajrccm.157.4.9704134. PubMed DOI

DOBBE JGG, STREEKSTRA GJ, ATASEVER B, Van ZIJDERVELD R, INCE C. Measurement of functional microcirculatory geometry and velocity distributions using automated image analysis. Med Biol Eng Comput. 2008;46:659–670. doi: 10.1007/s11517-008-0349-4. PubMed DOI PMC

DOMSIC RT, DEZFULIAN C, SHOUSHTARI A, IVANCO D, KENNY E, KWOH CK, MEDSGER TA, CHAMPION HC. Endothelial dysfunction is present only in the microvasculature and microcirculation of early diffuse systemic sclerosis patients. Clin Exp Rheumatol. 2014;32:154–160. PubMed PMC

DONATO AJ, MACHIN DR, LESNIEWSKI LA. Mechanisms of Dysfunction in the Aging Vasculature and Role in Age-Related Disease. Circ Res. 2018;123(7):825–848. doi: 10.1161/CIRCRESAHA.118.312563. PubMed DOI PMC

FOX B, HARRIS RA. Oral antioxidants improve endothelial function in patients with cystic fibrosis. J Invest Med. 2013;61:455.

GOEDHART PT, KHALILZADA M, BEZEMER R, MERZA J, INCE C. Sidestream Dark Field (SDF) imaging: a novel stroboscopic LED ring-based imaging modality for clinical assessment of the microcirculation. Opt Express. 2007;15:15101–15114. doi: 10.1364/OE.15.015101. PubMed DOI

HADI ARH, CARR SC, SUWAIDI JA. Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome. Vasc Health Risk Manag. 2005;1:183–198. PubMed PMC

HAMBURG NM, KEYES MJ, LARSON MG, VASAN RS, SCHNABEL R, PRYDE MM, MITCHELL GF, SHEFFY J, VITA JA, BENJAMIN EJ. Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study. Circulation. 2008;117:2467–2474. doi: 10.1161/CIRCULATIONAHA.107.748574. PubMed DOI PMC

HASHIMOTO R, KURATA T, SEKINE M, NAKANO K, OHNISHI T, HANEISHI H. Two-wavelength oximetry of tissue microcirculation based on sidestream dark-field imaging. J Biomed Opt. 2018;24:1–8. doi: 10.1117/1.JBO.24.3.031013. PubMed DOI PMC

HECTOR A, GRIESE M, HARTL D. Oxidative stress in cystic fibrosis lung disease: an early event, but worth targeting. Eur Respir J. 2014;44:17–19. doi: 10.1183/09031936.00038114. PubMed DOI

HENNO P, MAUREY C, DANEL C, BONNETTE P, SOUILAMAS R, STERN M, DELCLAUX C, LÉVY M, ISRAËL-BIET D. Pulmonary vascular dysfunction in end-stage cystic fibrosis: role of NF-kappaB and endothelin-1. Eur Respir J. 2009;34:1329–1337. doi: 10.1183/09031936.00186908. PubMed DOI

HULL JH, GARROD R, HO TB, KNIGHT RK, COCKCROFT JR, SHALE DJ, BOLTON CE. Increased augmentation index in patients with cystic fibrosis. Eur Respir J. 2009;34:1322–1328. doi: 10.1183/09031936.00044009. PubMed DOI

HULL JH, GARROD R, HO TB, KNIGHT RK, COCKCROFT JR, SHALE DJ, BOLTON CE. Dynamic vascular changes following intravenous antibiotics in patients with cystic fibrosis. J Cyst Fibros. 2013;12:125–129. doi: 10.1016/j.jcf.2012.07.004. PubMed DOI

JEHLIČKA P, HUML M, SCHWARZ J, TREFIL L, KOBR J, SÝKORA J. Reactive Hyperaemia Index as a marker of endothelial dysfunction in children with Crohn’s disease is significantly lower than healthy controls. Acta Paediatrica. 2014;103:55–60. doi: 10.1111/apa.12467. PubMed DOI

JOHANSSON PI, STENSBALLE J, RASMUSSEN LS, OSTROWSKI SR. A high admission syndecan-1 level, a marker of endothelial glycocalyx degradation, is associated with inflammation, protein C depletion, fibrinolysis, and increased mortality in trauma patients. Ann Surg. 2011;254:194–200. doi: 10.1097/SLA.0b013e318226113d. PubMed DOI

KELLY AS, MARLATT AL, STEINBERGER L, DENGEL DR. Younger age is associated with lower reactive hyperemic index but not lower flow-mediated dilation among children and adolescents. Atherosclerosis. 2014;234:410–414. doi: 10.1016/j.atherosclerosis.2014.03.031. PubMed DOI PMC

KETTLE AJ, TURNER R, GANGELL CL, HARWOOD DT, KHALILOVA IS, CHAPMAN AL, WINTERBOURN CHC, SLY PD. Oxidation contributes to low glutathione in the airways of children with cystic fibrosis. Eur Respir J. 2014;44:122–129. doi: 10.1183/09031936.00170213. PubMed DOI

KITTNAR O. Selected sex related differences in pathophysiology of cardiovascular system. Physiol Res. 2020;69:21–31. doi: 10.33549/physiolres.934068. PubMed DOI PMC

KRAML P. The role of iron in the pathogenesis of atherosclerosis. Physiol Res. 2017;66:55–67. doi: 10.33549/physiolres.933589. PubMed DOI

MASOLA V, ZAZA G, ARDUINI A, ONISTO M, GAMBARO G. Endothelial glycocalyx as a regulator of fibrotic processes. Int J Mol Sci. 2021;22:2996. doi: 10.3390/ijms22062996. PubMed DOI PMC

MASOPUSTOVÁ A, JEHLIČKA P, HUML M, VOTAVA T, TREFIL L, KRESLOVÁ M, SÝKORA J. Plethysmographic and biochemical markers in the diagnosis of endothelial dysfunction in pediatric acute lymphoblastic leukemia survivors-new applications. Physiol Res. 2018a;67:903–909. doi: 10.33549/physiolres.933754. PubMed DOI

MASOPUSTOVÁ A. Endothelial dysfunction in Children and Young Adults: A combined Diagnostic Approach of Plethysmographic and Biochemical Markers. In: MASOPUSTOVÁ A, KRESLOVÁ M, SÝKORA J, JEHLIČKA P, TREFIL L, KOBR J, editors. Advances in Health and Disease. 1st ed. New York: Nova Science Publishers; 2018b. pp. 189–202.

MORRISON KM, DYAL L, CONNER W, HELDEN E, NEWKIRK L, YUSUF S, LONN E. Cardiovascular risk factors and non-invasive assessment of subclinical atherosclerosis in youth. Atherosclerosis. 2010;208:501–505. doi: 10.1016/j.atherosclerosis.2009.07.034. PubMed DOI

NIEUWDORP M, MEUWESE MC, VINK H, HOEKSTRA JB, KASTELEIN JJ, STROES ES. The endothelial glycocalyx: a potential barrier between health and vascular disease. Curr Opin Lipidol. 2005;16:507–511. doi: 10.1097/01.mol.0000181325.08926.9c. PubMed DOI

NOWAK JK, WOJSYK-BANASZAK I, MĄDRY E, WYKRĘTOWICZ A, KRZYŻANOWSKA P, DRZYMAŁA-CZYŻ S, NOWICKA A, POGORZELSKI A, SAPIEJKA E, SKORUPA W, SZCZEPANIK M, LISOWSKA A, WALKOWIAK J. Increased soluble VCAM-1 and normal P-selectin in cystic fibrosis: a cross-sectional study. Lung. 2017;195:445–453. doi: 10.1007/s00408-017-0029-y. PubMed DOI PMC

OLVEIRA G, OLVEIRA C, DORADO A, GARCÍA-FUENTES E, RUBIO E, TINAHONES F, SORIGUER F, MURRI M. Cellular and plasma oxidative stress biomarkers are raised in adults with bronchiectasis. Clin Nutr. 2013;32:112–117. doi: 10.1016/j.clnu.2012.06.002. PubMed DOI

OSIKA W, MONTGOMERY SM, DANGARDT F, WÄHRBORG P, GAN LM, TIDEMAN E, FRIBERG P. Anger, depression and anxiety associated with endothelial function in childhood and adolescence. Arch Dis Child. 2011;96:38–43. doi: 10.1136/adc.2008.152777. PubMed DOI

POORE S, BERRY B, EIDSON D, MCKIE KT, HARRIS RA. Evidence of vascular endothelial dysfunction in young patients with cystic fibrosis. Chest. 2013;143:939–945. doi: 10.1378/chest.12-1934. PubMed DOI

POORE TS, TAYLOR-COUSARB JL, ZEMANICK ET. Cardiovascular complications in cystic fibrosis: A review of the literature. J Cyst Fibros. 2021;14:1569–1993. doi: 10.1016/j.jcf.2021.04.016. PubMed DOI

REVERRI EJ, MORRISSEY BM, CROSS CE, STEINBERG FM. Inflammation, oxidative stress, and cardiovascular disease risk factors in adults with cystic fibrosis. Free Radic Biol Med. 2014;76:261–277. doi: 10.1016/j.freeradbiomed.2014.08.005. PubMed DOI

RODRIGUEZ-MIGUELEZ P, THOMAS J, SEIGLER N, CRANDALL R, MCKIE KT, FORSEEN C, HARRIS RA. Evidence of microvascular dysfunction in patients with cystic fibrosis. Am J Physiol Heart Circ Physiol. 2016;310:1479–1485. doi: 10.1152/ajpheart.00136.2016. PubMed DOI PMC

ROSS R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999;340:115–126. doi: 10.1056/NEJM199901143400207. PubMed DOI

SELAMET TIERNEY ES, NEWBURGER JW, GAUVREAU K, GEVA J, COOGAN E, COLAN SD, DE FERRANTI SD. Endothelial pulse amplitude testing: feasibility and reproducibility in adolescents. J Pediatr. 2009;154:901–905. doi: 10.1016/j.jpeds.2008.12.028. PubMed DOI

SLÍVA J, CHARALAMBOUS C, BULTAS J, KARETOVÁ D. A new strategy for the treatment of atherothrombosis - inhibition of inflammation. Physiol Res. 2019;68:17–30. doi: 10.33549/physiolres.934327. PubMed DOI

TUCKER MA, FOX BM, SEIGLER N, RODRIGUEZ-MIGUELEZ P, LOONEY J, THOMAS J, McKIE KT, FORSEEN C, DAVISON GW, HARRIS RA. Endothelial dysfunction in cystic fibrosis: role of oxidative stress. Oxid Med Cell Longev. 2019;2019:1629638. doi: 10.1155/2019/1629638. PubMed DOI PMC

VÍTEK L. Bilirubin and atherosclerotic diseases. Physiol Res. 2017;66:11–20. doi: 10.33549/physiolres.933581. PubMed DOI

VRABLÍK M. Atherosclerosis - so well-known and still mysterious. Physiol Res. 2017;66:i–ii.

WIDLANSKY ME, GOCKE N, KEANEY JF, JR, VITA JA. The clinical implications of endotehlial dysfunction. J Am Coll Cardiol. 2003;42:1149–1160. doi: 10.1016/S0735-1097(03)00994-X. PubMed DOI

YILMAZ O, AFSAR B, ORTIZ A, KANBAY M. The role of endothelial glycocalyx in health and disease. Clin Kidney J. 2019;12:611–619. doi: 10.1093/ckj/sfz042. PubMed DOI PMC

YAMAOKA-TOJO M. Endothelial glycocalyx damage as a systemic inflammatory microvascular endotheliopathy in COVID-19. Biomed J. 2020;43:399–413. doi: 10.1016/j.bj.2020.08.007. PubMed DOI PMC

YANG Y, HAEGER SM, SUFLITA MA, ZHANG F, DAILEY KL, COLBERT JF, FORD JA, PICON MA, STEARMAN RS, LIN L, LIU X, HAN X, LINHARDT RJ, SCHMIDT EP. Fibroblast growth factor signaling mediates pulmonary endothelial glycocalyx reconstitution. Am J Respir Cell Mol Biol. 2017;56:727–737. doi: 10.1165/rcmb.2016-0338OC. PubMed DOI PMC

Circulating Serum Cystatin C as an Independent Risk Biomarker for Vascular Endothelial Dysfunction in Patients with COVID-19-Associated Multisystem Inflammatory Syndrome in Children (MIS-C): A Prospective Observational Study

Bronchial Asthma as a Cardiovascular Risk Factor: A Prospective Observational Study